JP2015516813A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015516813A5 JP2015516813A5 JP2015509207A JP2015509207A JP2015516813A5 JP 2015516813 A5 JP2015516813 A5 JP 2015516813A5 JP 2015509207 A JP2015509207 A JP 2015509207A JP 2015509207 A JP2015509207 A JP 2015509207A JP 2015516813 A5 JP2015516813 A5 JP 2015516813A5
- Authority
- JP
- Japan
- Prior art keywords
- activatable antibody
- egfr
- seq
- cancer
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical class 0.000 claims description 37
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 20
- 229920001184 polypeptide Polymers 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 150000007523 nucleic acids Chemical class 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 238000010494 dissociation reaction Methods 0.000 claims description 5
- 230000005593 dissociations Effects 0.000 claims description 5
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical group CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 3
- 102000001301 EGF receptor Human genes 0.000 claims 34
- 108060006698 EGF receptor Proteins 0.000 claims 34
- 239000003795 chemical substances by application Substances 0.000 claims 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 208000035475 disorder Diseases 0.000 claims 12
- 108091005804 Peptidases Proteins 0.000 claims 10
- 239000004365 Protease Substances 0.000 claims 10
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 10
- 102000004190 Enzymes Human genes 0.000 claims 9
- 108090000790 Enzymes Proteins 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 8
- 125000006850 spacer group Chemical group 0.000 claims 6
- 239000000758 substrate Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 206010014733 Endometrial cancer Diseases 0.000 claims 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 201000004681 Psoriasis Diseases 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 206010017758 gastric cancer Diseases 0.000 claims 4
- 208000005017 glioblastoma Diseases 0.000 claims 4
- 201000010536 head and neck cancer Diseases 0.000 claims 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- 201000000062 kidney sarcoma Diseases 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 201000000849 skin cancer Diseases 0.000 claims 4
- 201000011549 stomach cancer Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- -1 chromophore Substances 0.000 claims 3
- 239000002872 contrast media Substances 0.000 claims 3
- 239000000975 dye Substances 0.000 claims 3
- 239000007850 fluorescent dye Substances 0.000 claims 3
- 239000012216 imaging agent Substances 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229910021645 metal ion Inorganic materials 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000000873 masking effect Effects 0.000 claims 2
- 108010093470 monomethyl auristatin E Proteins 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- JARGNLJYKBUKSJ-KGZKBUQUSA-N (2r)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydrobromide Chemical compound Br.OC(=O)[C@H](N)CCC(=O)N[C@H](CO)C(=O)NCC(O)=O JARGNLJYKBUKSJ-KGZKBUQUSA-N 0.000 claims 1
- WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical group CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 claims 1
- 101500021165 Aplysia californica Myomodulin-A Proteins 0.000 claims 1
- 108010053070 Glutathione Disulfide Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 206010039509 Scab Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 108010044540 auristatin Proteins 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical group C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims 1
- 229930195731 calicheamicin Natural products 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical group CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims 1
- 229930188854 dolastatin Natural products 0.000 claims 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical group COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims 1
- 229960005501 duocarmycin Drugs 0.000 claims 1
- 229930184221 duocarmycin Natural products 0.000 claims 1
- 108010044804 gamma-glutamyl-seryl-glycine Proteins 0.000 claims 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 claims 1
- 108700026078 glutathione trisulfide Proteins 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 21
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 21
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 21
- 125000003275 alpha amino acid group Chemical group 0.000 description 13
- 241000894007 species Species 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261639796P | 2012-04-27 | 2012-04-27 | |
| US61/639,796 | 2012-04-27 | ||
| US201261662204P | 2012-06-20 | 2012-06-20 | |
| US61/662,204 | 2012-06-20 | ||
| US201361749220P | 2013-01-04 | 2013-01-04 | |
| US61/749,220 | 2013-01-04 | ||
| US201361749529P | 2013-01-07 | 2013-01-07 | |
| US61/749,529 | 2013-01-07 | ||
| US201361763237P | 2013-02-11 | 2013-02-11 | |
| US61/763,237 | 2013-02-11 | ||
| PCT/US2013/038540 WO2013163631A2 (en) | 2012-04-27 | 2013-04-26 | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019017216A Division JP2019108331A (ja) | 2012-04-27 | 2019-02-01 | 上皮成長因子受容体を結合する活性化可能抗体及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015516813A JP2015516813A (ja) | 2015-06-18 |
| JP2015516813A5 true JP2015516813A5 (OSRAM) | 2017-10-12 |
Family
ID=49484042
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015509207A Pending JP2015516813A (ja) | 2012-04-27 | 2013-04-26 | 上皮成長因子受容体を結合する活性化可能抗体及びその使用方法 |
| JP2019017216A Pending JP2019108331A (ja) | 2012-04-27 | 2019-02-01 | 上皮成長因子受容体を結合する活性化可能抗体及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019017216A Pending JP2019108331A (ja) | 2012-04-27 | 2019-02-01 | 上皮成長因子受容体を結合する活性化可能抗体及びその使用方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (6) | US9120853B2 (OSRAM) |
| EP (1) | EP2841093A4 (OSRAM) |
| JP (2) | JP2015516813A (OSRAM) |
| KR (1) | KR102138743B1 (OSRAM) |
| CN (2) | CN104540518A (OSRAM) |
| AU (2) | AU2013251310B2 (OSRAM) |
| BR (1) | BR112014026354A2 (OSRAM) |
| CA (1) | CA2871458C (OSRAM) |
| CO (1) | CO7160045A2 (OSRAM) |
| HK (1) | HK1204581A1 (OSRAM) |
| IL (2) | IL235331A0 (OSRAM) |
| IN (1) | IN2014MN02164A (OSRAM) |
| MX (1) | MX2014013041A (OSRAM) |
| PE (1) | PE20150605A1 (OSRAM) |
| PH (1) | PH12014502641B1 (OSRAM) |
| RU (1) | RU2713121C2 (OSRAM) |
| SG (1) | SG11201406943XA (OSRAM) |
| WO (1) | WO2013163631A2 (OSRAM) |
| ZA (2) | ZA201407715B (OSRAM) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102482347B (zh) | 2009-01-12 | 2017-04-26 | 希托马克斯医疗有限责任公司 | 修饰抗体组合物及其制备和使用方法 |
| ES2890501T3 (es) | 2009-03-02 | 2022-01-20 | Massachusetts Inst Technology | Métodos y productos para la creación de perfiles enzimáticos in vivo |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| CA2871458C (en) | 2012-04-27 | 2020-06-23 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| AU2014204015A1 (en) * | 2013-01-04 | 2015-07-09 | Cytomx Therapeutics, Inc. | Compositions and methods for detecting protease activity in biological systems |
| KR20150132864A (ko) * | 2013-03-15 | 2015-11-26 | 애브비 인코포레이티드 | 항체 약물 접합체(adc) 정제 |
| US10633453B2 (en) | 2013-05-28 | 2020-04-28 | Kaohsiung Medical University | Antibody locker for the inactivation of protein drug |
| JP6847660B2 (ja) | 2013-06-07 | 2021-03-24 | マサチューセッツ インスティテュート オブ テクノロジー | リガンドをコードする合成バイオマーカーのアフィニティベースの検出 |
| EP3016980B1 (en) * | 2013-07-05 | 2020-05-06 | Formation Biologics Inc. | Egfr antibody conjugates |
| HRP20220553T1 (hr) | 2013-07-25 | 2022-06-10 | Cytomx Therapeutics Inc. | Polispecifična protutijela, polispecifična protutijela koja se mogu aktivirati i postupci uporabe navedenih protutijela |
| US20150087810A1 (en) | 2013-09-25 | 2015-03-26 | Cytomx Therapeutics, Inc. | Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use Thereof |
| US9540440B2 (en) | 2013-10-30 | 2017-01-10 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| WO2015089283A1 (en) * | 2013-12-11 | 2015-06-18 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
| BR112016017649B1 (pt) * | 2014-01-31 | 2024-01-30 | Cytomx Therapeutics, Inc | Polipeptídeo isolado compreendendo substratos de matriptase e de ativador do plasminogênio u e outras porções cliváveis, composição farmacêutica compreendendo o dito polipeptídeo, bem como métodos para produzir e fabricar um polipeptídeo isolado compreendendo uma porção clivável e uso da composição farmacêutica e quantidade terapeuticamente eficaz da dita composição no tratamento de um distúrbio ou doença |
| DK3536776T5 (da) | 2014-04-29 | 2024-09-02 | Novartis Ag | Hidtil ukendte vertebratceller og fremgangsmåder til rekombinant ekspression af et polypeptid af interesse |
| WO2016014974A2 (en) * | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| CN104910275A (zh) * | 2014-12-04 | 2015-09-16 | 上海张江生物技术有限公司 | 一种新型抗表皮生长因子受体抗体、其制备方法及用途 |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| WO2016149201A2 (en) * | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| CN107849133B (zh) * | 2015-05-04 | 2022-08-23 | 西托姆克斯治疗公司 | 抗cd166抗体、可活化抗cd166抗体及其使用方法 |
| US10233244B2 (en) * | 2015-05-04 | 2019-03-19 | Cytomx Therapeutics, Inc. | Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereof |
| SG10201913762QA (en) | 2015-05-04 | 2020-03-30 | Cytomx Therapeutics Inc | Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof |
| KR20190080992A (ko) | 2015-05-21 | 2019-07-08 | 하푼 테라퓨틱스, 인크. | 삼중특이성 결합 단백질 및 사용 방법 |
| CN108431018A (zh) * | 2015-06-12 | 2018-08-21 | 王天欣 | 药物应用中蛋白质修饰的方法 |
| WO2016204966A1 (en) | 2015-06-16 | 2016-12-22 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| WO2016210447A1 (en) * | 2015-06-26 | 2016-12-29 | University Of Southern California | Masking chimeric antigen receptor t cells for tumor-specific activation |
| WO2017019729A1 (en) | 2015-07-27 | 2017-02-02 | The General Hospital Corporation | Antibody derivatives with conditionally enabled effector function |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| CN105399830B (zh) * | 2015-09-08 | 2019-11-19 | 北京天广实生物技术股份有限公司 | 抗egfr人源化单克隆抗体、其制备方法及用途 |
| CN106519037B (zh) * | 2015-09-11 | 2019-07-23 | 科济生物医药（上海）有限公司 | 可活化的嵌合受体 |
| EA039736B1 (ru) * | 2015-09-15 | 2022-03-04 | Сайтомкс Терапьютикс, Инк. | Анти-pdl1-антитела, активируемые анти-pdl1-антитела и способы их применения |
| CN108472365A (zh) | 2015-10-30 | 2018-08-31 | 艾丽塔生物治疗剂公司 | 用于肿瘤转导的组合物和方法 |
| CN108602872A (zh) | 2015-10-30 | 2018-09-28 | 艾丽塔生物治疗剂公司 | 用于治疗癌症的组合物和方法 |
| ES2873846T5 (en) | 2015-11-19 | 2025-06-23 | Revitope Ltd | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| AU2017219859A1 (en) * | 2016-02-16 | 2018-08-09 | Dana-Farber Cancer Institute, Inc. | Immunotherapy compositions and methods |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| WO2017177115A1 (en) | 2016-04-08 | 2017-10-12 | Massachusetts Institute Of Technology | Methods to specifically profile protease activity at lymph nodes |
| CA3022928A1 (en) | 2016-05-05 | 2017-11-09 | Massachusetts Institute Of Technology | Methods and uses for remotely triggered protease activity measurements |
| CA3042679A1 (en) * | 2016-11-03 | 2018-05-11 | Bristol-Myers Squibb Company | Activatable anti-ctla-4 antibodies and uses thereof |
| EA201991353A1 (ru) | 2016-12-09 | 2019-11-29 | Двухвалентные антитела, маскированные спирализованными спиралями | |
| AU2018231127A1 (en) * | 2017-03-09 | 2019-09-19 | Cytomx Therapeutics, Inc. | CD147 antibodies, activatable CD147 antibodies, and methods of making and use thereof |
| AU2018248327B2 (en) | 2017-04-07 | 2024-10-10 | Massachusetts Institute Of Technology | Methods to spatially profile protease activity in tissue and sections |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| JP2020531045A (ja) | 2017-07-14 | 2020-11-05 | シートムエックス セラピューティクス，インコーポレイテッド | 抗ｃｄ１６６抗体およびその使用 |
| AU2018304711B2 (en) * | 2017-07-20 | 2025-04-10 | Cytomx Therapeutics, Inc. | Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof |
| EP3668545A2 (en) | 2017-08-16 | 2020-06-24 | Bristol-Myers Squibb Company | Prodruggable antibodies, prodrugs thereof, and methods of use and making |
| KR20240170847A (ko) | 2017-09-08 | 2024-12-04 | 다케다 야쿠힌 고교 가부시키가이샤 | 제약된 조건적으로 활성화된 결합 단백질 |
| PL3694529T3 (pl) | 2017-10-13 | 2024-12-16 | Harpoon Therapeutics, Inc. | Trójswoiste białka i sposoby zastosowania |
| IL321773A (en) | 2017-10-14 | 2025-08-01 | Cytomx Therapeutics Inc | Activatable antibodies and methods for preparing them |
| US20200385440A1 (en) * | 2017-12-07 | 2020-12-10 | Janux Therapeutics, Inc. | Modified bispecific t cell receptors |
| WO2019118918A1 (en) | 2017-12-15 | 2019-06-20 | Aleta Biotherapeutics Inc. | Cd19 variants |
| CA3089287A1 (en) | 2018-02-08 | 2019-08-15 | Genentech, Inc. | Bispecific antigen-binding molecules and methods of use |
| WO2019173332A1 (en) | 2018-03-05 | 2019-09-12 | Massachusetts Institute Of Technology | Inhalable nanosensors with volatile reporters and uses thereof |
| CN112005304A (zh) | 2018-03-20 | 2020-11-27 | 西托姆克斯治疗公司 | 用于哺乳动物受试者中的可活化抗体种类的定量药理学建模的系统和方法 |
| EP3794022A1 (en) | 2018-05-14 | 2021-03-24 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| JP7460609B2 (ja) | 2018-05-14 | 2024-04-02 | ウェアウルフ セラピューティクス， インコーポレイテッド | 活性化可能なインターロイキン－２ポリペプチド及びその使用方法 |
| MX2020012217A (es) | 2018-05-14 | 2021-03-02 | Harpoon Therapeutics Inc | Porción de unión para activación condicional de moléculas de inmunoglobulina. |
| US20210269530A1 (en) * | 2018-05-14 | 2021-09-02 | Harpoon Therapeutics, Inc. | Conditionally activated binding protein comprising a sterically occluded target binding domain |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| US12173349B2 (en) | 2018-09-25 | 2024-12-24 | Massachusetts Institute Of Technology | Lung protease nanosensors and uses thereof |
| CN120248140A (zh) | 2018-12-06 | 2025-07-04 | 西托姆克斯治疗公司 | 基质金属蛋白酶可裂解的和丝氨酸或半胱氨酸蛋白酶可裂解的底物及其使用方法 |
| US11153281B2 (en) | 2018-12-06 | 2021-10-19 | Bank Of America Corporation | Deploying and utilizing a dynamic data stenciling system with a smart linking engine |
| US11835522B2 (en) | 2019-01-17 | 2023-12-05 | Massachusetts Institute Of Technology | Sensors for detecting and imaging of cancer metastasis |
| CN120484127A (zh) | 2019-03-05 | 2025-08-15 | 武田药品工业有限公司 | 受约束的条件性活化的结合蛋白 |
| JP7754723B2 (ja) | 2019-05-14 | 2025-10-15 | ウェアウルフ セラピューティクス， インコーポレイテッド | 分離部分及びその使用方法 |
| US20230220105A1 (en) * | 2019-06-06 | 2023-07-13 | Janux Therapeutics, Inc. | Tumor activated t cell engagers and methods of use thereof |
| US20220251206A1 (en) | 2019-06-11 | 2022-08-11 | Bristol-Myers Squibb Company | Anti-ctla4 antibody prodruggable (probody) at a cdr position |
| CN114650844A (zh) * | 2019-09-23 | 2022-06-21 | 西托姆克斯治疗公司 | 抗cd47抗体、可活化抗cd47抗体及其使用方法 |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| AR120741A1 (es) | 2019-12-13 | 2022-03-16 | Genentech Inc | Anticuerpos anti-ly6g6d y métodos de uso |
| EP4090686A4 (en) * | 2020-01-17 | 2024-03-27 | Immune Targeting Inc. | PRO-ANTIBODY REDUCING OFF-TARGET TOXICITY |
| AU2021208642B2 (en) * | 2020-01-17 | 2025-06-05 | Immunelogic Therapeutics, Inc. | Pro-antibody that reduces off-target toxicity |
| EP4337697A4 (en) * | 2020-04-04 | 2025-05-14 | Janux Therapeutics, Inc. | Compositions and methods related to tumor-activated antibodies against EGFR and effector cell antigens |
| KR20220166814A (ko) | 2020-04-09 | 2022-12-19 | 싸이톰스 테라퓨틱스, 인크. | 활성화 가능한 항체를 함유하는 조성물 |
| US11512113B2 (en) * | 2020-08-11 | 2022-11-29 | Janux Therapeutics, Inc. | Cleavable linker compositions and methods |
| MX2023006817A (es) | 2020-12-09 | 2023-08-14 | Janux Therapeutics Inc | Composiciones y metodos relacionados con anticuerpos activados por tumores dirigidos a psma y antigenos de celulas efectoras. |
| KR20240118749A (ko) | 2021-10-15 | 2024-08-05 | 싸이톰스 테라퓨틱스, 인크. | 활성화 가능한 폴리펩타이드 복합체 |
| PE20241343A1 (es) | 2021-10-15 | 2024-07-03 | Cytomx Therapeutics Inc | Complejo polipeptidico activable |
| WO2023064955A1 (en) | 2021-10-15 | 2023-04-20 | Cytomx Therapeutics, Inc. | Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex |
| AU2023215789A1 (en) * | 2022-02-04 | 2024-08-01 | Zytox Therapeutics Ab | Fusion protein comprising an egfr-binding domain and a masking domain |
| AR129061A1 (es) | 2022-04-13 | 2024-07-10 | Genentech Inc | Composiciones farmacéuticas de mosunetuzumab y métodos de uso |
| TWI877756B (zh) * | 2022-08-31 | 2025-03-21 | 中國醫藥大學 | 抗meEGFR抗體、其抗原結合片段及其用途 |
| WO2025235515A1 (en) | 2024-05-07 | 2025-11-13 | Cytomx Therapeutics, Inc. | Activatable polypeptide complex formulations |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| EP0279862B1 (en) | 1986-08-28 | 1993-11-03 | Teijin Limited | Cytocidal antibody complex and process for its preparation |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US6455247B1 (en) | 1996-01-23 | 2002-09-24 | Board Of Trustees Of The Leland Stanford Junior University | Methods for screening for transdominant effector peptides and RNA molecules |
| GB9603507D0 (en) | 1996-02-20 | 1996-04-17 | Isis Innovation | Antibody variants |
| TW505653B (en) | 1996-02-26 | 2002-10-11 | Meiji Seika Co | Triterpene derivatives possessing an effect of treating liver diseases and pharmacentical compositions containing the same |
| AU724326B2 (en) | 1996-09-09 | 2000-09-14 | Zealand Pharmaceuticals A/S | Peptide prodrugs containing an alpha-hydroxyacid linker |
| EP2275557A1 (en) | 2000-04-12 | 2011-01-19 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1286700A2 (en) * | 2000-06-01 | 2003-03-05 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| JP4334866B2 (ja) | 2000-10-09 | 2009-09-30 | アイシス イノヴェイション リミテッド | 治療用抗体 |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| CN1463270A (zh) * | 2001-05-31 | 2003-12-24 | 梅达莱克斯公司 | 细胞毒素、其有用的前体药物、连接基团和稳定剂 |
| US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| AU2003265866A1 (en) | 2002-09-03 | 2004-03-29 | Vit Lauermann | Targeted release |
| US20040111757A1 (en) * | 2002-12-05 | 2004-06-10 | Dongxiao Zhang | Multiplex system for production and screening of monoclonal antibodies |
| US8088387B2 (en) * | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| AR048098A1 (es) * | 2004-03-15 | 2006-03-29 | Wyeth Corp | Conjugados de caliqueamicina |
| CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
| US7666817B2 (en) | 2005-08-31 | 2010-02-23 | The Regents Of The University Of California | Cellular libraries of peptide sequences (CLiPS) and methods of using the same |
| WO2007105027A1 (en) * | 2006-03-10 | 2007-09-20 | Diatos | Anticancer drugs conjugated to antibody via an enzyme cleavable linker |
| HRP20140172T1 (hr) | 2006-05-30 | 2014-03-28 | Genentech, Inc. | Protutijela i imunokonjugati kao i njihove uporabe |
| CA2654000A1 (en) | 2006-06-06 | 2008-05-22 | Genentech, Inc. | Anti-dll4 antibodies and methods using same |
| WO2008101177A2 (en) * | 2007-02-16 | 2008-08-21 | University Of Virginia Patent Foundation | Ige antibodies to chimeric or humanized igg therapeutic monoclonal antibodies as a screening test for anaphylaxis |
| EP2487190A3 (en) | 2007-07-13 | 2012-11-14 | Bac Ip B.V. | Single-domain antigen-binding proteins that bind mammalian IgG |
| WO2009014726A1 (en) | 2007-07-26 | 2009-01-29 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
| CA3128656A1 (en) | 2007-08-22 | 2009-02-26 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
| UY31504A1 (es) * | 2007-11-30 | 2009-07-17 | Construcciones de union de antigenos | |
| EP2277044B1 (en) | 2008-05-13 | 2015-06-17 | Genentech, Inc. | Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry |
| US20100189727A1 (en) * | 2008-12-08 | 2010-07-29 | Tegopharm Corporation | Masking Ligands For Reversible Inhibition Of Multivalent Compounds |
| US20110178279A1 (en) * | 2009-08-03 | 2011-07-21 | Williams John C | Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies |
| US8895702B2 (en) * | 2008-12-08 | 2014-11-25 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies |
| CN102482347B (zh) | 2009-01-12 | 2017-04-26 | 希托马克斯医疗有限责任公司 | 修饰抗体组合物及其制备和使用方法 |
| CA2761310C (en) | 2009-05-07 | 2017-02-28 | Charles S. Craik | Antibodies and methods of use thereof |
| JP6066732B2 (ja) | 2010-03-05 | 2017-01-25 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 標的免疫調節抗体および融合タンパク質に基づく組成物および方法 |
| US9193791B2 (en) | 2010-08-03 | 2015-11-24 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| US20150044208A1 (en) | 2011-09-23 | 2015-02-12 | Technophage, Investigaçäo E Desenvolvimento Em Biotecnologia, Sa | Modified Albumin-Binding Domains and Uses Thereof to Improve Pharmacokinetics |
| CA2871458C (en) | 2012-04-27 | 2020-06-23 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| US9517276B2 (en) | 2013-06-04 | 2016-12-13 | Cytomx Therapeutics, Inc. | Compositions and methods for conjugating activatable antibodies |
| HRP20220553T1 (hr) | 2013-07-25 | 2022-06-10 | Cytomx Therapeutics Inc. | Polispecifična protutijela, polispecifična protutijela koja se mogu aktivirati i postupci uporabe navedenih protutijela |
| US9540440B2 (en) | 2013-10-30 | 2017-01-10 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| WO2015089283A1 (en) | 2013-12-11 | 2015-06-18 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
-
2013
- 2013-04-26 CA CA2871458A patent/CA2871458C/en not_active Expired - Fee Related
- 2013-04-26 AU AU2013251310A patent/AU2013251310B2/en not_active Ceased
- 2013-04-26 RU RU2014147684A patent/RU2713121C2/ru active
- 2013-04-26 US US13/872,052 patent/US9120853B2/en active Active
- 2013-04-26 KR KR1020147032521A patent/KR102138743B1/ko not_active Expired - Fee Related
- 2013-04-26 MX MX2014013041A patent/MX2014013041A/es active IP Right Grant
- 2013-04-26 JP JP2015509207A patent/JP2015516813A/ja active Pending
- 2013-04-26 BR BR112014026354A patent/BR112014026354A2/pt not_active IP Right Cessation
- 2013-04-26 HK HK15105286.5A patent/HK1204581A1/xx unknown
- 2013-04-26 EP EP13780884.6A patent/EP2841093A4/en not_active Withdrawn
- 2013-04-26 SG SG11201406943XA patent/SG11201406943XA/en unknown
- 2013-04-26 PE PE2014001901A patent/PE20150605A1/es active IP Right Grant
- 2013-04-26 IN IN2164MUN2014 patent/IN2014MN02164A/en unknown
- 2013-04-26 WO PCT/US2013/038540 patent/WO2013163631A2/en not_active Ceased
- 2013-04-26 CN CN201380033414.8A patent/CN104540518A/zh active Pending
- 2013-04-26 CN CN201910284451.5A patent/CN110078827A/zh active Pending
-
2014
- 2014-10-23 ZA ZA2014/07715A patent/ZA201407715B/en unknown
- 2014-10-26 IL IL235331A patent/IL235331A0/en active IP Right Grant
- 2014-10-27 CO CO14237235A patent/CO7160045A2/es unknown
- 2014-11-26 PH PH12014502641A patent/PH12014502641B1/en unknown
-
2015
- 2015-07-31 US US14/815,111 patent/US9545442B2/en active Active
- 2015-10-21 ZA ZA2015/07859A patent/ZA201507859B/en unknown
-
2016
- 2016-12-16 US US15/381,972 patent/US9889211B2/en active Active
-
2018
- 2018-01-19 US US15/875,947 patent/US10709799B2/en active Active
- 2018-05-10 AU AU2018203262A patent/AU2018203262A1/en not_active Abandoned
-
2019
- 2019-02-01 JP JP2019017216A patent/JP2019108331A/ja active Pending
- 2019-04-02 IL IL265788A patent/IL265788A/en unknown
-
2020
- 2020-06-04 US US16/892,973 patent/US11890354B2/en active Active
-
2023
- 2023-12-26 US US18/396,187 patent/US20240398998A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015516813A5 (OSRAM) | ||
| JP7073487B2 (ja) | 操作された抗体化合物およびこれらの抱合体 | |
| RU2014147684A (ru) | Активируемые антитела, которые связываются с рецептором эпидермального фактора роста, и способы их применения | |
| US11760795B2 (en) | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer | |
| US10533053B2 (en) | Nucleic acids encoding activatable antibodies that bind epidermal growth factor receptor | |
| JP2023159099A (ja) | マトリックスメタロプロテイナーゼ基質及び他の切断可能部分並びにそれらの使用方法 | |
| JP6835586B2 (ja) | マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法 | |
| KR101523705B1 (ko) | Ｓｐａｒｃ 결합 ｓｃｆｖｓ | |
| RU2011133819A (ru) | Композиции модифицированных антител, способы их получения и применения | |
| US20100189727A1 (en) | Masking Ligands For Reversible Inhibition Of Multivalent Compounds | |
| JP2012514982A5 (OSRAM) | ||
| JP2022523200A (ja) | 活性化可能な免疫チェックポイント阻害剤とコンジュゲートされた活性化可能な抗体の組み合わせ療法 | |
| WO2021183717A1 (en) | Proteinaceous therapeutics | |
| KR20140104944A (ko) | 항-ａｘｌ 항체 및 그의 용도 | |
| CN105744944B (zh) | 免疫系统调节器 | |
| CA2793647A1 (en) | Prophylaxis of colorectal and gastrointestinal cancer | |
| WO2011135040A1 (en) | Fluorescent antibody fusion protein, its production and use | |
| EP2267125B1 (en) | Cancer cell migration and cancer cell invasion inhibitor | |
| CN106279404A (zh) | 一种可溶且稳定的异质二聚tcr | |
| EP1956032B1 (en) | Monoclonal antibody directed against cd166 and method for production thereof | |
| CN114025795B (zh) | 使用靶向her2的双特异性抗原结合构建体治疗胆道癌的方法 | |
| CN117510642A (zh) | 一种全基因编码的双靶向嵌合体及其应用 | |
| CN112823168A (zh) | 结合her2的四聚体多肽 | |
| WO2022105922A1 (zh) | 源自于ssx2抗原的短肽 | |
| US20240366814A1 (en) | Treatment of bladder cancer with radiolabeled antibodies targeting cdcp1 |